June陈
2021-09-15
Like.
Moderna stock jumped 4% in morning trading<blockquote>Moderna 股价早盘上涨 4%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":882113340,"tweetId":"882113340","gmtCreate":1631666528180,"gmtModify":1631890119733,"author":{"id":4087997917943030,"idStr":"4087997917943030","authorId":4087997917943030,"authorIdStr":"4087997917943030","name":"June陈","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":43,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Like.</p></body></html>","htmlText":"<html><head></head><body><p>Like.</p></body></html>","text":"Like.","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/882113340","repostId":1118676828,"repostType":4,"repost":{"id":"1118676828","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631631830,"share":"https://www.laohunote.com/m/news/1118676828?lang=zh_CN&edition=full","pubTime":"2021-09-14 23:03","market":"us","language":"en","title":"Moderna stock jumped 4% in morning trading<blockquote>Moderna 股价早盘上涨 4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1118676828","media":"Tiger Newspress","summary":"Moderna stock jumped 4% in morning trading as a recent study found that the Moderna COVID-19 vaccine","content":"<p>Moderna stock jumped 4% in morning trading as a recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</p><p><blockquote>Moderna 股价在早盘交易中上涨 4%，因为最近的一项研究发现 Moderna COVID-19 疫苗产生的抗体水平高于辉瑞-BioNTech 疫苗。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/289c5ec428971234976d932651a5f86d\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <ul> <li>A recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</li> <li>This is possibly due to its higher mRNA content and a longer waiting period between doses.</li> <li>Antibody tests are not entirely predictive of the body’s immunity against COVID-19.</li> </ul> A recent study found that the Moderna COVID-19 vaccine produced twice as many antibodies in recipients as the Pfizer-BioNTech vaccine.</p><p><blockquote><ul><li>最近的一项研究发现，Moderna新冠肺炎疫苗产生的抗体水平高于辉瑞-BioNTech疫苗。</li><li>这可能是由于其较高的mRNA含量和较长的剂量之间的等待期。</li><li>抗体检测并不能完全预测人体对 COVID-19 的免疫力。</li></ul>最近的一项研究发现，Moderna新冠肺炎疫苗在接受者体内产生的抗体数量是辉瑞-BioNTech疫苗的两倍。</blockquote></p><p> The August study, published in <i>JAMA</i>, compared the antibody levels of 1647 healthcare workers before and six to 10 weeks after vaccination. The researchers observed significantly higher antibody levels among the recipients of the Moderna vaccine compared to the recipients of the Pfizer-BioNTech vaccine.</p><p><blockquote>八月的研究，发表于<i>贾玛</i>比较了1647名医护人员接种疫苗前和接种后6至10周的抗体水平。研究人员观察到，与辉瑞-BioNTech疫苗的接受者相比，Moderna疫苗的接受者的抗体水平明显更高。</blockquote></p><p> Among all the participants who had a previous COVID-19 infection, those who were vaccinated with the Moderna vaccine still carried more antibodies.</p><p><blockquote>在所有曾感染过 COVID-19 的参与者中，接种 Moderna 疫苗的参与者仍然携带更多抗体。</blockquote></p><p> However, more research is needed to understand whether the difference in antibody levels leads to different levels of protection against the virus. Experts stress that testing for antibodies isn't the only way of measuring protection.</p><p><blockquote>然而，需要更多的研究来了解抗体水平的差异是否导致对病毒的不同保护水平。专家强调，抗体测试并不是衡量保护的唯一方法。</blockquote></p><p> <b>Why Does Moderna Produce Higher Antibody Levels?</b></p><p><blockquote><b>为什么Moderna会产生更高的抗体水平？</b></blockquote></p><p> According to the authors of the study, the Moderna COVID-19 vaccine contains more mRNA and requires a longer waiting period than Pfizer-BioNTech, which may have played a role.</p><p><blockquote>根据该研究的作者，Moderna新冠肺炎疫苗含有更多的mRNA，需要比辉瑞-BioNTech更长的等待期，这可能起到了一定的作用。</blockquote></p><p> “It is also possible that the mRNA itself used in the Moderna vaccine may have led to this difference independent of the dose in the vaccine or the timing of the two shots,\"Richard Martinello, MD, Yale Medicine infectious diseases specialist and associate professor of medicine and pediatrics at the Yale School of Medicine, who was not involved in the study, tells Verywell.</p><p><blockquote>“也有可能是 Moderna 疫苗中使用的 mRNA 本身导致了这种差异，而与疫苗中的剂量或两次注射的时间无关，”耶鲁大学医学传染病专家、耶鲁大学医学院医学和儿科学副教授理查德-马丁内洛（Richard Martinello）医学博士告诉 Verywell，他没有参与这项研究。</blockquote></p><p> The Moderna vaccine contains more mRNA within the vaccine compared to the Pfizer dosage. And doses are given 28 days apart, compared to 21 days for the Pfizer vaccine.</p><p><blockquote>与辉瑞剂量相比，Moderna疫苗含有更多的mRNA。剂量间隔28天，而辉瑞疫苗间隔21天。</blockquote></p><p> Still, further research is needed to understand why Moderna produced more antibodies. Experts still aren't sure if varying antibody levels translate to a difference in protection against COVID-19.</p><p><blockquote>尽管如此，还需要进一步的研究来了解为什么Moderna产生了更多的抗体。专家们仍然不确定不同的抗体水平是否会转化为对 COVID-19 保护的差异。</blockquote></p><p> <b>Antibody Tests Don’t Tell the Whole Story</b></p><p><blockquote><b>抗体检测并不能说明全部情况</b></blockquote></p><p> The study has notable limitations since it focused solely on healthcare workers and did not include data on cellular immunity.</p><p><blockquote>这项研究有明显的局限性，因为它只关注医护人员，不包括细胞免疫的数据。</blockquote></p><p> “Antibody levels have been found to provide a good measure of one’s protection against infection,” Martinello says. “However, it is known that cellular immunity plays a key role in the protection against and response to COVID. This is much more difficult to measure so it is not a routine test available from clinical laboratories. Therefore, while it is possible that the Moderna vaccine may be found to be more protective than the Pfizer vaccine, that remains to be seen.”</p><p><blockquote>“马丁内洛说：”研究发现，抗体水平可以很好地衡量一个人对感染的保护。“然而，众所周知，细胞免疫在预防和应对 COVID 方面起着关键作用。这一点更难测量，因此临床实验室无法进行常规检测。因此，虽然 Moderna 疫苗有可能比辉瑞疫苗更具保护作用，但这还有待观察。”</blockquote></p><p> A May study found that antibody levels can be predictive of protection from COVID-19 infection, but the researchers acknowledged that it's important to study T cell and B cell memory responses as well.</p><p><blockquote>5月份的一项研究发现，抗体水平可以预测对新冠肺炎感染的保护，但研究人员承认，研究T细胞和B细胞的记忆反应也很重要。</blockquote></p><p> Although antibody levels are much simpler and cheaper to measure, and higher levels are likely to be more protective, they’re not a good measure of the degree and/or duration of protection an individual has against COVID-19,Stanley H. Weiss, MD, professor of medicine at the Rutgers New Jersey Medical School and professor of biostatistics at the Rutgers School of Public Health, tells Verywell.</p><p><blockquote>罗格斯大学新泽西医学院医学教授兼罗格斯大学公共卫生学院生物统计学教授斯坦利-H-韦斯（Stanley H. Weiss）医学博士告诉 Verywell，虽然抗体水平的测量要简单得多，成本也更低，而且抗体水平越高，保护作用也可能越强，但它们并不能很好地衡量一个人对 COVID-19 的保护程度和/或持续时间。</blockquote></p><p> Earlier this year, the Food and Drug Administration (FDA) issued guidance saying that antibody tests should not be used to assess COVID-19 immunity after vaccination.3Researchers say that antibody tests are valuable public health tools that have very little use for individuals, and should not influence personal decision-making.</p><p><blockquote>今年早些时候，美国食品药品监督管理局（FDA）发布了指导方针，称抗体测试不应用于评估疫苗接种后的新冠肺炎免疫力。3研究人员表示，抗体测试是有价值的公共卫生工具，对个人几乎没有用处，也不应影响个人决策。</blockquote></p><p> “There is ample data showing that some persons without any detectable antibodies have good protection due to cellular immunity,” Weiss says. “There is also ample data of breakthrough infection among persons who have anti-Covid antibodies.”</p><p><blockquote>“韦斯说：”有大量数据表明，一些没有任何可检测抗体的人由于细胞免疫而具有良好的保护作用。“也有大量数据表明，在体内有抗Covid抗体的人群中出现了突破性感染”。</blockquote></p><p> A March study found that cellular immunity remains robust six months after natural infection even though antibodies against the virus may fall below detectable levels. The findings show promise that COVID-19 vaccines elicit a similar response in the body.</p><p><blockquote>三月份的一项研究发现，尽管针对病毒的抗体可能低于可检测的水平，但自然感染六个月后细胞免疫力仍然很强。研究结果表明，新冠肺炎疫苗有望在体内引发类似的反应。</blockquote></p><p> “In an individual person for clinical purposes, and especially outside of a carefully designed research study, I recommend against antibody testing,” Weiss says. “Neither a positive nor negative result gives you definitive information. My recommendation is for a decision to be based on general clinical criteria, not on an antibody test.”</p><p><blockquote>“韦斯说：”出于临床目的，尤其是在精心设计的研究之外，我建议不要对个人进行抗体检测。“阳性和阴性结果都不能提供明确的信息。我的建议是，根据一般临床标准做出决定，而不是根据抗体检测。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock jumped 4% in morning trading<blockquote>Moderna 股价早盘上涨 4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock jumped 4% in morning trading<blockquote>Moderna 股价早盘上涨 4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-09-14 23:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock jumped 4% in morning trading as a recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</p><p><blockquote>Moderna 股价在早盘交易中上涨 4%，因为最近的一项研究发现 Moderna COVID-19 疫苗产生的抗体水平高于辉瑞-BioNTech 疫苗。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/289c5ec428971234976d932651a5f86d\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <ul> <li>A recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.</li> <li>This is possibly due to its higher mRNA content and a longer waiting period between doses.</li> <li>Antibody tests are not entirely predictive of the body’s immunity against COVID-19.</li> </ul> A recent study found that the Moderna COVID-19 vaccine produced twice as many antibodies in recipients as the Pfizer-BioNTech vaccine.</p><p><blockquote><ul><li>最近的一项研究发现，Moderna新冠肺炎疫苗产生的抗体水平高于辉瑞-BioNTech疫苗。</li><li>这可能是由于其较高的mRNA含量和较长的剂量之间的等待期。</li><li>抗体检测并不能完全预测人体对 COVID-19 的免疫力。</li></ul>最近的一项研究发现，Moderna新冠肺炎疫苗在接受者体内产生的抗体数量是辉瑞-BioNTech疫苗的两倍。</blockquote></p><p> The August study, published in <i>JAMA</i>, compared the antibody levels of 1647 healthcare workers before and six to 10 weeks after vaccination. The researchers observed significantly higher antibody levels among the recipients of the Moderna vaccine compared to the recipients of the Pfizer-BioNTech vaccine.</p><p><blockquote>八月的研究，发表于<i>贾玛</i>比较了1647名医护人员接种疫苗前和接种后6至10周的抗体水平。研究人员观察到，与辉瑞-BioNTech疫苗的接受者相比，Moderna疫苗的接受者的抗体水平明显更高。</blockquote></p><p> Among all the participants who had a previous COVID-19 infection, those who were vaccinated with the Moderna vaccine still carried more antibodies.</p><p><blockquote>在所有曾感染过 COVID-19 的参与者中，接种 Moderna 疫苗的参与者仍然携带更多抗体。</blockquote></p><p> However, more research is needed to understand whether the difference in antibody levels leads to different levels of protection against the virus. Experts stress that testing for antibodies isn't the only way of measuring protection.</p><p><blockquote>然而，需要更多的研究来了解抗体水平的差异是否导致对病毒的不同保护水平。专家强调，抗体测试并不是衡量保护的唯一方法。</blockquote></p><p> <b>Why Does Moderna Produce Higher Antibody Levels?</b></p><p><blockquote><b>为什么Moderna会产生更高的抗体水平？</b></blockquote></p><p> According to the authors of the study, the Moderna COVID-19 vaccine contains more mRNA and requires a longer waiting period than Pfizer-BioNTech, which may have played a role.</p><p><blockquote>根据该研究的作者，Moderna新冠肺炎疫苗含有更多的mRNA，需要比辉瑞-BioNTech更长的等待期，这可能起到了一定的作用。</blockquote></p><p> “It is also possible that the mRNA itself used in the Moderna vaccine may have led to this difference independent of the dose in the vaccine or the timing of the two shots,\"Richard Martinello, MD, Yale Medicine infectious diseases specialist and associate professor of medicine and pediatrics at the Yale School of Medicine, who was not involved in the study, tells Verywell.</p><p><blockquote>“也有可能是 Moderna 疫苗中使用的 mRNA 本身导致了这种差异，而与疫苗中的剂量或两次注射的时间无关，”耶鲁大学医学传染病专家、耶鲁大学医学院医学和儿科学副教授理查德-马丁内洛（Richard Martinello）医学博士告诉 Verywell，他没有参与这项研究。</blockquote></p><p> The Moderna vaccine contains more mRNA within the vaccine compared to the Pfizer dosage. And doses are given 28 days apart, compared to 21 days for the Pfizer vaccine.</p><p><blockquote>与辉瑞剂量相比，Moderna疫苗含有更多的mRNA。剂量间隔28天，而辉瑞疫苗间隔21天。</blockquote></p><p> Still, further research is needed to understand why Moderna produced more antibodies. Experts still aren't sure if varying antibody levels translate to a difference in protection against COVID-19.</p><p><blockquote>尽管如此，还需要进一步的研究来了解为什么Moderna产生了更多的抗体。专家们仍然不确定不同的抗体水平是否会转化为对 COVID-19 保护的差异。</blockquote></p><p> <b>Antibody Tests Don’t Tell the Whole Story</b></p><p><blockquote><b>抗体检测并不能说明全部情况</b></blockquote></p><p> The study has notable limitations since it focused solely on healthcare workers and did not include data on cellular immunity.</p><p><blockquote>这项研究有明显的局限性，因为它只关注医护人员，不包括细胞免疫的数据。</blockquote></p><p> “Antibody levels have been found to provide a good measure of one’s protection against infection,” Martinello says. “However, it is known that cellular immunity plays a key role in the protection against and response to COVID. This is much more difficult to measure so it is not a routine test available from clinical laboratories. Therefore, while it is possible that the Moderna vaccine may be found to be more protective than the Pfizer vaccine, that remains to be seen.”</p><p><blockquote>“马丁内洛说：”研究发现，抗体水平可以很好地衡量一个人对感染的保护。“然而，众所周知，细胞免疫在预防和应对 COVID 方面起着关键作用。这一点更难测量，因此临床实验室无法进行常规检测。因此，虽然 Moderna 疫苗有可能比辉瑞疫苗更具保护作用，但这还有待观察。”</blockquote></p><p> A May study found that antibody levels can be predictive of protection from COVID-19 infection, but the researchers acknowledged that it's important to study T cell and B cell memory responses as well.</p><p><blockquote>5月份的一项研究发现，抗体水平可以预测对新冠肺炎感染的保护，但研究人员承认，研究T细胞和B细胞的记忆反应也很重要。</blockquote></p><p> Although antibody levels are much simpler and cheaper to measure, and higher levels are likely to be more protective, they’re not a good measure of the degree and/or duration of protection an individual has against COVID-19,Stanley H. Weiss, MD, professor of medicine at the Rutgers New Jersey Medical School and professor of biostatistics at the Rutgers School of Public Health, tells Verywell.</p><p><blockquote>罗格斯大学新泽西医学院医学教授兼罗格斯大学公共卫生学院生物统计学教授斯坦利-H-韦斯（Stanley H. Weiss）医学博士告诉 Verywell，虽然抗体水平的测量要简单得多，成本也更低，而且抗体水平越高，保护作用也可能越强，但它们并不能很好地衡量一个人对 COVID-19 的保护程度和/或持续时间。</blockquote></p><p> Earlier this year, the Food and Drug Administration (FDA) issued guidance saying that antibody tests should not be used to assess COVID-19 immunity after vaccination.3Researchers say that antibody tests are valuable public health tools that have very little use for individuals, and should not influence personal decision-making.</p><p><blockquote>今年早些时候，美国食品药品监督管理局（FDA）发布了指导方针，称抗体测试不应用于评估疫苗接种后的新冠肺炎免疫力。3研究人员表示，抗体测试是有价值的公共卫生工具，对个人几乎没有用处，也不应影响个人决策。</blockquote></p><p> “There is ample data showing that some persons without any detectable antibodies have good protection due to cellular immunity,” Weiss says. “There is also ample data of breakthrough infection among persons who have anti-Covid antibodies.”</p><p><blockquote>“韦斯说：”有大量数据表明，一些没有任何可检测抗体的人由于细胞免疫而具有良好的保护作用。“也有大量数据表明，在体内有抗Covid抗体的人群中出现了突破性感染”。</blockquote></p><p> A March study found that cellular immunity remains robust six months after natural infection even though antibodies against the virus may fall below detectable levels. The findings show promise that COVID-19 vaccines elicit a similar response in the body.</p><p><blockquote>三月份的一项研究发现，尽管针对病毒的抗体可能低于可检测的水平，但自然感染六个月后细胞免疫力仍然很强。研究结果表明，新冠肺炎疫苗有望在体内引发类似的反应。</blockquote></p><p> “In an individual person for clinical purposes, and especially outside of a carefully designed research study, I recommend against antibody testing,” Weiss says. “Neither a positive nor negative result gives you definitive information. My recommendation is for a decision to be based on general clinical criteria, not on an antibody test.”</p><p><blockquote>“韦斯说：”出于临床目的，尤其是在精心设计的研究之外，我建议不要对个人进行抗体检测。“阳性和阴性结果都不能提供明确的信息。我的建议是，根据一般临床标准做出决定，而不是根据抗体检测。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118676828","content_text":"Moderna stock jumped 4% in morning trading as a recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.\n\n\nA recent study found that the Moderna COVID-19 vaccine produces higher antibody levels than the Pfizer-BioNTech vaccine.\nThis is possibly due to its higher mRNA content and a longer waiting period between doses.\nAntibody tests are not entirely predictive of the body’s immunity against COVID-19.\n\nA recent study found that the Moderna COVID-19 vaccine produced twice as many antibodies in recipients as the Pfizer-BioNTech vaccine.\nThe August study, published in JAMA, compared the antibody levels of 1647 healthcare workers before and six to 10 weeks after vaccination. The researchers observed significantly higher antibody levels among the recipients of the Moderna vaccine compared to the recipients of the Pfizer-BioNTech vaccine.\nAmong all the participants who had a previous COVID-19 infection, those who were vaccinated with the Moderna vaccine still carried more antibodies.\nHowever, more research is needed to understand whether the difference in antibody levels leads to different levels of protection against the virus. Experts stress that testing for antibodies isn't the only way of measuring protection.\nWhy Does Moderna Produce Higher Antibody Levels?\nAccording to the authors of the study, the Moderna COVID-19 vaccine contains more mRNA and requires a longer waiting period than Pfizer-BioNTech, which may have played a role.\n“It is also possible that the mRNA itself used in the Moderna vaccine may have led to this difference independent of the dose in the vaccine or the timing of the two shots,\"Richard Martinello, MD, Yale Medicine infectious diseases specialist and associate professor of medicine and pediatrics at the Yale School of Medicine, who was not involved in the study, tells Verywell.\nThe Moderna vaccine contains more mRNA within the vaccine compared to the Pfizer dosage. And doses are given 28 days apart, compared to 21 days for the Pfizer vaccine.\nStill, further research is needed to understand why Moderna produced more antibodies. Experts still aren't sure if varying antibody levels translate to a difference in protection against COVID-19.\nAntibody Tests Don’t Tell the Whole Story\nThe study has notable limitations since it focused solely on healthcare workers and did not include data on cellular immunity.\n“Antibody levels have been found to provide a good measure of one’s protection against infection,” Martinello says. “However, it is known that cellular immunity plays a key role in the protection against and response to COVID. This is much more difficult to measure so it is not a routine test available from clinical laboratories. Therefore, while it is possible that the Moderna vaccine may be found to be more protective than the Pfizer vaccine, that remains to be seen.”\nA May study found that antibody levels can be predictive of protection from COVID-19 infection, but the researchers acknowledged that it's important to study T cell and B cell memory responses as well.\nAlthough antibody levels are much simpler and cheaper to measure, and higher levels are likely to be more protective, they’re not a good measure of the degree and/or duration of protection an individual has against COVID-19,Stanley H. Weiss, MD, professor of medicine at the Rutgers New Jersey Medical School and professor of biostatistics at the Rutgers School of Public Health, tells Verywell.\nEarlier this year, the Food and Drug Administration (FDA) issued guidance saying that antibody tests should not be used to assess COVID-19 immunity after vaccination.3Researchers say that antibody tests are valuable public health tools that have very little use for individuals, and should not influence personal decision-making.\n“There is ample data showing that some persons without any detectable antibodies have good protection due to cellular immunity,” Weiss says. “There is also ample data of breakthrough infection among persons who have anti-Covid antibodies.”\nA March study found that cellular immunity remains robust six months after natural infection even though antibodies against the virus may fall below detectable levels. The findings show promise that COVID-19 vaccines elicit a similar response in the body.\n“In an individual person for clinical purposes, and especially outside of a carefully designed research study, I recommend against antibody testing,” Weiss says. “Neither a positive nor negative result gives you definitive information. My recommendation is for a decision to be based on general clinical criteria, not on an antibody test.”","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2672,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":5,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/882113340"}
精彩评论